Isradipine, a calcium-entry blocker, decreases vascular [125-I]low-density lipoprotein entry in hypercholesterolemic rabbits.
In 72 male rabbits aged 6 months, the endothelium of the abdominal aorta was abraded by a Fogarthy catheter. The animals were then fed a 1% cholesterol-supplemented diet for 4 weeks. In addition, half of the animals were treated for the entire period with isradipine (0.3 mg/kg daily), a dihydropyridine calcium antagonist; the other 36 animals served as controls. One hour and 3, 6, 12, 24, and 48 hours before the animals were killed, [125-I]low-density lipoprotein (LDL 10 microCi) was administered intravenously (i.v.) to six animals in each group. The [125-I]LDL entry was quantified in the abdominal aorta according to the type and presence of endothelial lining. Isradipine significantly reduced the [125-I]LDL entry at most time intervals. In parallel, an increase in vascular prostaglandin (PGI2) synthesis was noted, which might be the underlying mechanism for the decreased LDL entry.
Sinzinger
H
H
Atherosclerosis Research Group (ASF) Vienna, Austria.
Lupattelli
G
G
Virgolini
I
I
Gerakakis
A
A
Fitscha
P
P
Molinari
E
E
Angelberger
P
P
D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects / Q000378:metabolism; D001808:Blood Vessels / Q000187:drug effects / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D011464:Epoprostenol / Q000096:biosynthesis; D006937:Hypercholesterolemia / Q000378:metabolism*; D007457:Iodine Radioisotopes; D017275:Isradipine; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008297:Male; D011725:Pyridines / Q000494:pharmacology*; D011817:Rabbits
D002121:Calcium Channel Blockers; D007457:Iodine Radioisotopes; D008077:Lipoproteins, LDL; D011725:Pyridines; D011464:Epoprostenol; D017275:Isradipine